129 related articles for article (PubMed ID: 17882664)
1. Ubiquitin ligases in cancer: ushers for degradation.
Newton K; Vucic D
Cancer Invest; 2007 Sep; 25(6):502-13. PubMed ID: 17882664
[TBL] [Abstract][Full Text] [Related]
2. E3 ubiquitin ligases as cancer targets and biomarkers.
Sun Y
Neoplasia; 2006 Aug; 8(8):645-54. PubMed ID: 16925947
[TBL] [Abstract][Full Text] [Related]
3. RING-, HECT-, and RBR-type E3 Ubiquitin Ligases: Involvement in Human Cancer.
Uchida C; Kitagawa M
Curr Cancer Drug Targets; 2016; 16(2):157-74. PubMed ID: 26560116
[TBL] [Abstract][Full Text] [Related]
4. Molecular targeting of E3 ligases--a therapeutic approach for cancer.
Lakshmanan M; Bughani U; Duraisamy S; Diwan M; Dastidar S; Ray A
Expert Opin Ther Targets; 2008 Jul; 12(7):855-70. PubMed ID: 18554154
[TBL] [Abstract][Full Text] [Related]
5. Examining protein stability and its relevance for plant growth and development.
Schwechheimer C; Willige BC; Zourelidou M; Dohmann EM
Methods Mol Biol; 2009; 479():147-71. PubMed ID: 19083189
[TBL] [Abstract][Full Text] [Related]
6. E3 ubiquitin ligases in cancer and implications for therapies.
Wang D; Ma L; Wang B; Liu J; Wei W
Cancer Metastasis Rev; 2017 Dec; 36(4):683-702. PubMed ID: 29043469
[TBL] [Abstract][Full Text] [Related]
7. Novel Insights Into E3 Ubiquitin Ligase in Cancer Chemoresistance.
Yang L; Chen J; Huang X; Zhang E; He J; Cai Z
Am J Med Sci; 2018 Apr; 355(4):368-376. PubMed ID: 29661351
[TBL] [Abstract][Full Text] [Related]
8. The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications.
Burger AM; Seth AK
Eur J Cancer; 2004 Oct; 40(15):2217-29. PubMed ID: 15454246
[TBL] [Abstract][Full Text] [Related]
9. Ubiquitin-Conjugating Enzymes in Cancer.
Bui QT; Hong JH; Kwak M; Lee JY; Lee PC
Cells; 2021 Jun; 10(6):. PubMed ID: 34199813
[TBL] [Abstract][Full Text] [Related]
10. E3 ligases: a potential multi-drug target for different types of cancers and neurological disorders.
Saravanan KM; Kannan M; Meera P; Bharathkumar N; Anand T
Future Med Chem; 2022 Jan; 14(3):187-201. PubMed ID: 35100004
[TBL] [Abstract][Full Text] [Related]
11. Overview of approaches for screening for ubiquitin ligase inhibitors.
Sun Y
Methods Enzymol; 2005; 399():654-63. PubMed ID: 16338387
[TBL] [Abstract][Full Text] [Related]
12. A ubiquitin ligase transfers preformed polyubiquitin chains from a conjugating enzyme to a substrate.
Li W; Tu D; Brunger AT; Ye Y
Nature; 2007 Mar; 446(7133):333-7. PubMed ID: 17310145
[TBL] [Abstract][Full Text] [Related]
13. The infected cell protein 0 of herpes simplex virus 1 dynamically interacts with proteasomes, binds and activates the cdc34 E2 ubiquitin-conjugating enzyme, and possesses in vitro E3 ubiquitin ligase activity.
Van Sant C; Hagglund R; Lopez P; Roizman B
Proc Natl Acad Sci U S A; 2001 Jul; 98(15):8815-20. PubMed ID: 11447293
[TBL] [Abstract][Full Text] [Related]
14. E2 conjugating enzymes must disengage from their E1 enzymes before E3-dependent ubiquitin and ubiquitin-like transfer.
Eletr ZM; Huang DT; Duda DM; Schulman BA; Kuhlman B
Nat Struct Mol Biol; 2005 Oct; 12(10):933-4. PubMed ID: 16142244
[TBL] [Abstract][Full Text] [Related]
15. Viral hijacking of cellular ubiquitination pathways as an anti-innate immunity strategy.
Chen M; Gerlier D
Viral Immunol; 2006; 19(3):349-62. PubMed ID: 16987055
[TBL] [Abstract][Full Text] [Related]
16. Ubiquitin becomes ubiquitous in cancer: emerging roles of ubiquitin ligases and deubiquitinases in tumorigenesis and as therapeutic targets.
Shi D; Grossman SR
Cancer Biol Ther; 2010 Oct; 10(8):737-47. PubMed ID: 20930542
[TBL] [Abstract][Full Text] [Related]
17. Promising new therapeutic targets for regulation of inflammation and immunity: RING-type E3 ubiquitin ligases.
Bulatov E; Valiullina A; Sayarova R; Rizvanov A
Immunol Lett; 2018 Oct; 202():44-51. PubMed ID: 30099009
[TBL] [Abstract][Full Text] [Related]
18. Orchestra for assembly and fate of polyubiquitin chains.
Kuhlbrodt K; Mouysset J; Hoppe T
Essays Biochem; 2005; 41():1-14. PubMed ID: 16250894
[TBL] [Abstract][Full Text] [Related]
19. Autoantigen Ro52 is an E3 ubiquitin ligase.
Wada K; Kamitani T
Biochem Biophys Res Commun; 2006 Jan; 339(1):415-21. PubMed ID: 16297862
[TBL] [Abstract][Full Text] [Related]
20. Selective multifaceted E3 ubiquitin ligases barricade extreme defense: Potential therapeutic targets for neurodegeneration and ageing.
Upadhyay A; Amanullah A; Chhangani D; Mishra R; Mishra A
Ageing Res Rev; 2015 Nov; 24(Pt B):138-59. PubMed ID: 26247845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
